DBPIO
June 17, 2025
Company Presentation
Tools/Drug Development Support Tech
153C
DPBIO is a pioneering innovator based in California, specializing in high-throughput droplet microfluidic technology and providing cutting-edge life science solutions to researchers and industry leaders worldwide.
At DPBIO, we integrate advanced microfluidic technology with life sciences to develop comprehensive solutions, including microfluidic chips, instruments, and reagents. Our flagship products—such as the CytoSpark® High-throughput Screening System, OMNIdrop System, Galaxy Single-Cell Analysis System, Nebula Digital PCR System, and ExoStar Extracellular Vesicle Analysis System—empower scientists in antibody discovery, enzyme evolution, strain screening, small-molecule drug screening, cancer research, early disease detection, viral quantification, and biopharmaceutical quality control.
Company HQ City:
Shenzhen
Company HQ State:
GuangDong
Company HQ Country:
China
Year Founded:
2018
Lead Product in Development:
CytoSpark® High-throughput Screening System -
CytoSpark@ CSP High-throughput Screening System is based on droplet microfluidics technology that enables the encapsulation, detection and screening of millions of cells in a single run. It exceeds the traditional screening throughput and provides more possibilities for screening more functional cells. In the field of antibody development, CytoSpark@ CSP High-throughput Screening System can accurately and efficiently screen millions of single B-cells in 1-2 days, providing a faster and more efficient solution for antibody development and accelerating the antibody drug development cycle.
CEO
Dr. Xu Xiaonan
Development Phase of Lead Product
Multiple Products in Market
What is your next catalyst (value inflection) update?
2025.09
Website
https://dp-bio.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}